Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pragmatic comparison of beta(2)-agonist side effects within the worldwide atosiban versus beta agonists study

Chan, Jerry ; Cabrol, Dominique ; Ingemarsson, Ingemar LU ; Marsal, Karel LU ; Moutquin, Jean-Marie and Fisk, Nicholas M. (2006) In European Journal of Obstetrics, Gynecology, and Reproductive Biology 128(1-2). p.135-141
Abstract
Objective: While beta(2)-agonists for the acute treatment of preterm labour unequivocally reduce the odds of delivery within 48 hand 7 days, they have been associated with substantial maternal and fetal side effects. We aimed to compare side effect profiles of beta(2)-agonist tocolytics. Study design: Pragmatic comparison of ritodrine, salbutamol and terbutaline from re-analysis of data obtained within three comparator arms of three simultaneous comparable randomised controlled trials of beta(2)-agonists against atosiban in 742 women in preterm labour. The prevalence of categoric side effects between treatment groups was analysed using a chi(2) test. The differences in continuous variables between treatment groups were analysed in analyses... (More)
Objective: While beta(2)-agonists for the acute treatment of preterm labour unequivocally reduce the odds of delivery within 48 hand 7 days, they have been associated with substantial maternal and fetal side effects. We aimed to compare side effect profiles of beta(2)-agonist tocolytics. Study design: Pragmatic comparison of ritodrine, salbutamol and terbutaline from re-analysis of data obtained within three comparator arms of three simultaneous comparable randomised controlled trials of beta(2)-agonists against atosiban in 742 women in preterm labour. The prevalence of categoric side effects between treatment groups was analysed using a chi(2) test. The differences in continuous variables between treatment groups were analysed in analyses of covariance. Results: The prevalence of categoric side effects was similar with the three drugs, with the exception of the subjective symptom of palpitations (ritodrine 24.0%, terbutaline 9.3% and salbutamol 12.3%, P = 0.003). There were also some differences in maternal diastolic blood pressure (P < 0.001) and serum glucose levels (P < 0.001), although these were small (<3 mmHg and <= 2.8 mmol/L, respectively) and clinically unimportant. Conclusion: Side effects were common with all three drugs. Thus, choosing one beta(2)-agonist over the other to minimise side effects has little rationale, especially now that safer tocolytics are available. (C) 2006 Elsevier Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
preterm labour, side effects, tocolysis, beta-agonist
in
European Journal of Obstetrics, Gynecology, and Reproductive Biology
volume
128
issue
1-2
pages
135 - 141
publisher
Elsevier
external identifiers
  • wos:000240909100025
  • scopus:33748370534
  • pmid:16504369
ISSN
0301-2115
DOI
10.1016/j.ejogrb.2006.01.030
language
English
LU publication?
yes
id
20c436cd-406c-4d31-a720-6227ffbb9770 (old id 389618)
date added to LUP
2016-04-01 11:51:45
date last changed
2021-08-10 03:19:50
@article{20c436cd-406c-4d31-a720-6227ffbb9770,
  abstract     = {Objective: While beta(2)-agonists for the acute treatment of preterm labour unequivocally reduce the odds of delivery within 48 hand 7 days, they have been associated with substantial maternal and fetal side effects. We aimed to compare side effect profiles of beta(2)-agonist tocolytics. Study design: Pragmatic comparison of ritodrine, salbutamol and terbutaline from re-analysis of data obtained within three comparator arms of three simultaneous comparable randomised controlled trials of beta(2)-agonists against atosiban in 742 women in preterm labour. The prevalence of categoric side effects between treatment groups was analysed using a chi(2) test. The differences in continuous variables between treatment groups were analysed in analyses of covariance. Results: The prevalence of categoric side effects was similar with the three drugs, with the exception of the subjective symptom of palpitations (ritodrine 24.0%, terbutaline 9.3% and salbutamol 12.3%, P = 0.003). There were also some differences in maternal diastolic blood pressure (P &lt; 0.001) and serum glucose levels (P &lt; 0.001), although these were small (&lt;3 mmHg and &lt;= 2.8 mmol/L, respectively) and clinically unimportant. Conclusion: Side effects were common with all three drugs. Thus, choosing one beta(2)-agonist over the other to minimise side effects has little rationale, especially now that safer tocolytics are available. (C) 2006 Elsevier Ireland Ltd. All rights reserved.},
  author       = {Chan, Jerry and Cabrol, Dominique and Ingemarsson, Ingemar and Marsal, Karel and Moutquin, Jean-Marie and Fisk, Nicholas M.},
  issn         = {0301-2115},
  language     = {eng},
  number       = {1-2},
  pages        = {135--141},
  publisher    = {Elsevier},
  series       = {European Journal of Obstetrics, Gynecology, and Reproductive Biology},
  title        = {Pragmatic comparison of beta(2)-agonist side effects within the worldwide atosiban versus beta agonists study},
  url          = {http://dx.doi.org/10.1016/j.ejogrb.2006.01.030},
  doi          = {10.1016/j.ejogrb.2006.01.030},
  volume       = {128},
  year         = {2006},
}